Authors: | Riely, G. J.; Wood, D. E.; Ettinger, D. S.; Aisner, D. L.; Akerley, W.; Bauman, J. R.; Bharat, A.; Bruno, D. S.; Chang, J. Y.; Chirieac, L. R.; DeCamp, M.; Desai, A. P.; Dilling, T. J.; Dowell, J.; Durm, G. A.; Gettinger, S.; Grotz, T. E.; Gubens, M. A.; Juloori, A.; Lackner, R. P.; Lanuti, M.; Lin, J.; Loo, B. W. Jr; Lovly, C. M.; Maldonado, F.; Massarelli, E.; Morgensztern, D.; Mullikin, T. C.; Ng, T.; Owen, D.; Owen, D. H.; Patel, S. P.; Patil, T.; Polanco, P. M.; Riess, J.; Shapiro, T. A.; Singh, A. P.; Stevenson, J.; Tam, A.; Tanvetyanon, T.; Yanagawa, J.; Yang, S. C.; Yau, E.; Gregory, K. M.; Hang, L. |
Title: | Non–small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology |
Abstract: | The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers. © JNCCN—Journal of the National Comprehensive Cancer Network. |
Keywords: | genetics; cancer staging; neoplasm staging; carcinoma, non-small-cell lung; lung neoplasms; practice guideline; pathology; tumor marker; lung tumor; non small cell lung cancer; molecularly targeted therapy; molecular targeted therapy; procedures; humans; human; biomarkers, tumor |
Journal Title: | Journal of the National Comprehensive Cancer Network |
Volume: | 22 |
Issue: | 4 |
ISSN: | 1540-1405 |
Publisher: | Harborside Press |
Date Published: | 2024-05-01 |
Start Page: | 249 |
End Page: | 274 |
Language: | English |
DOI: | 10.6004/jnccn.2204.0023 |
PUBMED: | 38754467 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Article -- Source: Scopus |